secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058618
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q1 revenue $11.1M (+5.8%), net loss $18.7M; lowers 2024 revenue guidance to lower end
--------------------------------------------------------------------------------

- Commercial revenue $11.1M, up 5.8% YoY; gross margin 86.4%.
- Net loss $18.7M ($0.73/share) vs $9.2M loss ($0.37) in Q1 2023; operating expenses $26.8M.
- Full-year 2024 commercial revenue expected at lower end of $78.5-84.5M range, implying ~57% growth.
- Launched PermeaDerm biosynthetic wound matrix in US on March 23, 2024.
- RECELL GO FDA decision by May 30, 2024; cashflow breakeven targeted no later than Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000095017024058618/0000950170-24-058618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000095017024058618/rcel-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer